Prelude Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Prelude Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-12,900	Closed	-$560K	–	1517
2020 Q4	$560K	Sell	12,900 -37,100	-74%	-$2.51M	0.01%	685
2020 Q3	$2.15M	Buy	+50,000	New	+$2.48M	0.1%	146
2015 Q2	–	Sell	-143	Closed	-$6K	–	1679
2015 Q1	$6K	Buy	+143	New	+$6.29K	﹤0.01%	1858
2014 Q4	–	Sell	-129	Closed	-$14K	–	1882
2014 Q3	$14K	Sell	129 -28	-18%	-$3.65K	﹤0.01%	1769
2014 Q2	$19K	Buy	+157	New	+$19K	﹤0.01%	1726

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Prelude Capital Management's ARCT Position: Q3 2025 in Review

Prelude Capital Management sold out of Arcturus Therapeutics (ARCT) in Q3 2025, closing a stake of 23,160 shares — an estimated $301K sold.

Prelude Capital Management first reported a position in ARCT in Q3 2013 and held it in 23 quarters. The position peaked at $426K in Q1 2020. 136 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.

Prelude Capital Management reported no remaining Arcturus Therapeutics position as of Q3 2025 after selling out during the quarter.
Prelude Capital Management sold 23,160 Arcturus Therapeutics shares in Q3 2025, an estimated $301K.
Prelude Capital Management first reported a position in Arcturus Therapeutics in Q3 2013 and held it in 23 quarters.
Prelude Capital Management's Arcturus Therapeutics position peaked at $426K in Q1 2020.
136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.